PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMCB PharmaCyte Biotech, Inc.

Market Closed 12-05 16:00:00 EST

1.22

+0.01

+0.83%

盘后1.15

-0.07-5.74%

19:59 EST

High1.51	Low1.11	Vol22.09M
Open1.29	D1 Closing1.21	Amplitude33.06%
Mkt Cap8.29M	Tradable Cap7.41M	Total Shares6.80M
T/O29.37M	T/O Rate363.43%	Tradable Shares6.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMCB","market":"US","secType":"STK","nameCN":"PharmaCyte Biotech, Inc.","latestPrice":1.22,"timestamp":1764968400000,"preClose":1.21,"halted":0,"volume":22087405,"hourTrading":{"tag":"盘后","latestPrice":1.15,"preClose":1.22,"latestTime":"19:59 EST","volume":328424,"amount":378703.6804,"timestamp":1764982798502},"delay":0,"floatShares":6077485,"shares":6795779,"eps":0.006294,"marketStatus":"Market Closed","change":0.01,"latestTime":"12-05 16:00:00 EST","open":1.285,"high":1.51,"low":1.11,"amount":29369297.7436465,"amplitude":0.330579,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.006294,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.21,"preHourTrading":{"tag":"盘前","latestPrice":1.2897,"preClose":1.21,"latestTime":"09:29 EST","volume":2732218,"amount":3605573.6694744,"timestamp":1764944993509},"postHourTrading":{"tag":"盘后","latestPrice":1.15,"preClose":1.22,"latestTime":"19:59 EST","volume":328424,"amount":378703.6804,"timestamp":1764982798502},"volumeRatio":0.9673105401636922,"impliedVol":1.359,"impliedVolPercentile":0.92},"requestUrl":"/m/hq/s/PMCB","defaultTab":"news","newsList":[{"id":"2589848589","title":"PharmaCyte Biotech Inc - Receives Notice of Non-Compliance With Nasdaq Rule - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848589?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:05","pubTimestamp":1764972347,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2589848536","title":"PharmaCyte Biotech : Will Consider All Available Options to Regain Compliance, Including, IF Appropriate, Implementing Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848536?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:05","pubTimestamp":1764972347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0IU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2589366848","title":"PharmaCyte Biotech Faces Nasdaq Delisting Risk Over Bid Price Rule Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2589366848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589366848?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:01","pubTimestamp":1764972072,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550. The company now has 180 calendar days, until June 1, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved within this period, PharmaCyte may be eligible for an additional 180-day extension if other initial listing requirements are met. Failure to regain compliance could result in the company's securities being delisted from the Nasdaq Capital Market. The notice does not affect the company's business operations or its SEC reporting obligations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL70lRpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2586471515","title":"PharmaCyte sells Femasys stake, sees cash position rising to $20M","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471515","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471515?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:25","pubTimestamp":1764080720,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharmacyte-sells-femasys-stake-sees-cash-position-rising-to-20m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharmacyte-sells-femasys-stake-sees-cash-position-rising-to-20m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEMY","BK4539","PMCB","BK4584","BK4082","BK4139"],"gpt_icon":0},{"id":"2586795734","title":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment","url":"https://stock-news.laohu8.com/highlight/detail?id=2586795734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586795734?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080164,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10UM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2586479578","title":"PharmaCyte Biotech Inc: Plans to Continue Pursuing Value-Accretive Investment Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479578?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10UM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2584965182","title":"PharmaCyte Biotech Issues Correction to Financial Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965182?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:07","pubTimestamp":1763500045,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has issued an amendment to its current report, updating financial statements for the years ended December 31, 2024 and 2023. The amendment includes details on the issuance of Series G Preferred Stock and related warrants, as well as information about employee benefit plan contributions and changes to the Series G Certificate of Designations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2pPXHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2580497415","title":"PharmaCyte Biotech Inc. held a special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580497415","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580497415?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:06","pubTimestamp":1761941166,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. held a special meeting of stockholders on October 30, 2025. Stockholders approved the issuance of shares of common stock underlying convertible preferred stock and warrants. An amendment to the 2022 Equity Incentive Plan to increase the number of shares available for grant by 2,250,000 shares was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1fYCly:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2570385500","title":"PharmaCyte Biotech Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2570385500","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570385500?lang=en_us&edition=fundamental","pubTime":"2025-09-25 04:33","pubTimestamp":1758745987,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. will hold a special meeting of stockholders on October 30, 2025. During the meeting, shareholders will vote on several proposals, including: the issuance of convertible preferred stock and warrants in an amount equal to or in excess of 20% of the company's common stock outstanding before issuance; an amendment to the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan to increase the number of shares available for the grant of awards by 2,250,000 shares; and the potential adjournment of the meeting to a later date if additional proxies are needed or to establish a quorum. Other business that may properly come before the meeting will also be addressed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Bio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL3ywGqd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2567140306","title":"PharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2567140306","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567140306?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:01","pubTimestamp":1757970114,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(1.23) per share. This is a 164.74 percent decrease over earnings of $1.90 per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47680734/pharmacyte-biotech-q1-eps-1-23-down-from-1-90-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"PharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB"],"gpt_icon":0},{"id":"2565593858","title":"PharmaCyte Biotech Inc. Plans Name Change Following Investment in LightSolver Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2565593858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565593858?lang=en_us&edition=fundamental","pubTime":"2025-09-06 04:06","pubTimestamp":1757102798,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has published a report announcing its increased investment in TNF Pharmaceuticals, which is set to undergo a name and ticker symbol change to align with its new strategic focus on revolutionary computing technologies for cryptocurrency applications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL5jQ09h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2564388850","title":"PharmaCyte Biotech Inc - Increases Stake in Tnf Pharmaceuticals by $3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2564388850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564388850?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:20","pubTimestamp":1756819219,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nFWN3UP083:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMCB","BK4007","BK4139","TNFA"],"gpt_icon":0},{"id":"2564888113","title":"PharmaCyte Biotech Inc. Anticipates Name Change Following TNF Pharmaceuticals Stake Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2564888113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564888113?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:20","pubTimestamp":1756819214,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc.  announced an increased stake in TNF Pharmaceuticals and reported that TNF is expected to change its name and ticker symbol to align with its new strategy focused on cryptocurrency mining and blockchain applications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via Business Wire  on September 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL7zJMFn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2564638830","title":"Press Release: PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2564638830","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564638830?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:20","pubTimestamp":1756819200,"startTime":"0","endTime":"0","summary":"TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies. PharmaCyte Biotech, Inc.  , today announced that it has increased its stake in TNF Pharmaceuticals  by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. , a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed to expedite compute-sensitive computations by harnessing light for computation. This method is designed to reduce energy output by 90% while outpacing conventional graphics processing units, quantum computing and high-performance computing with greater speed and more efficiency. TNF is expected to change its name and ticker symbol to support the new strategy, which it expects to be applied to cryptocurrency mining and blockc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2560109578","title":"PharmaCyte Biotech Inc. Expands Financial Flexibility with $7 Million Financing to Support Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2560109578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560109578?lang=en_us&edition=fundamental","pubTime":"2025-08-20 21:15","pubTimestamp":1755695717,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has announced a significant expansion following the successful closing of a $7 million financing round. With this new funding, the company bolsters its financial position, now holding approximately $15.5 million in cash and over $30 million in securities. The additional capital will support PharmaCyte's ongoing business initiatives and strategic growth opportunities, according to Interim CEO Josh Silverman. This expansion is expected to bring substantial value to shareholders as the company advances its initiatives and explores new opportunities in line with its long-term strategy. Currently, PharmaCyte has around 6.8 million shares of common stock outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL22XNzK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2560312109","title":"PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2560312109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560312109?lang=en_us&edition=fundamental","pubTime":"2025-08-20 21:15","pubTimestamp":1755695700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nTUA2ZCFDN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2560886731","title":"PharmaCyte Biotech Secures $7 Million Through Private Placement Led by Existing Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2560886731","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560886731?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:15","pubTimestamp":1755522919,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has announced a $7 million capital raise through a securities purchase agreement with existing investors. The financing involves the sale of 7,000 shares of newly designated Series C convertible preferred stock, each valued at $1,000, convertible into 7,000,000 shares of common stock. Additionally, unregistered common stock purchase warrants are included, allowing the purchase of up to 7,000,000 shares of common stock. The private placement, led by GP Nurmenkari Inc. as the sole placement agent, is expected to close on or about August 19, 2025. This move is seen as a strong vote of confidence in PharmaCyte's future, enhancing its financial position and allowing the company to pursue strategic alternatives aimed at maximizing long-term shareholder returns.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL6gKMF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"gpt_icon":0},{"id":"2560955188","title":"PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2560955188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560955188?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:15","pubTimestamp":1755522914,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nFWN3UA09M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMCB"],"gpt_icon":0},{"id":"2558266541","title":"PharmaCyte Biotech Q4 EPS $1.54 Up From $(0.33) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2558266541","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558266541?lang=en_us&edition=fundamental","pubTime":"2025-08-11 21:44","pubTimestamp":1754919841,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly earnings of $1.54 per share. This is a 566.67 percent increase over losses of $(0.33) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47030803/pharmacyte-biotech-q4-eps-1-54-up-from-0-33-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB"],"gpt_icon":0},{"id":"2558564356","title":"PharmaCyte Biotech Reports No Revenue and Reduced Operating Expenses for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2558564356","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558564356?lang=en_us&edition=fundamental","pubTime":"2025-08-11 18:02","pubTimestamp":1754906522,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc., a biotechnology company focused on cellular therapies for cancer, released its annual report for the fiscal year ending April 30, 2025. The company reported no revenues for the fiscal years 2025 and 2024. Operating expenses totaled $4.38 million for the year ended April 30, 2025, marking a decrease of $4.14 million compared to the previous year. This reduction was primarily due to lower compensation, director fees, and legal and professional expenses, although research and development (R&D) expenses increased by $30,985 to $438,416. This rise in R&D spending was attributed to a new agreement with consultants to conduct further research into pancreatic cancer treatment. The company highlighted its efforts to prepare for a planned clinical trial in locally advanced pancreatic cancer . Looking ahead, PharmaCyte Biotech stated that its current cash reserves are expected to cover operating expenses for at least the next 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL1HDNxc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharmacyte.com","stockEarnings":[{"period":"1week","weight":0.577},{"period":"1month","weight":0.3781},{"period":"3month","weight":0.2964},{"period":"6month","weight":0.1961},{"period":"1year","weight":-0.2561},{"period":"ytd","weight":-0.2229}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.29659},{"month":2,"riseRate":0.571429,"avgChangeRate":0.119534},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.14342},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.05725},{"month":5,"riseRate":0.125,"avgChangeRate":-0.09845},{"month":6,"riseRate":0.5,"avgChangeRate":0.058308},{"month":7,"riseRate":0.25,"avgChangeRate":-0.101838},{"month":8,"riseRate":0.125,"avgChangeRate":-0.172017},{"month":9,"riseRate":0.625,"avgChangeRate":0.071622},{"month":10,"riseRate":0.25,"avgChangeRate":-0.073172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.078728},{"month":12,"riseRate":0.375,"avgChangeRate":0.05667}],"exchange":"NASDAQ","name":"PharmaCyte Biotech, Inc.","nameEN":"PharmaCyte Biotech, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PharmaCyte Biotech, Inc.(PMCB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PharmaCyte Biotech, Inc.,PMCB,PharmaCyte Biotech, Inc.股票,PharmaCyte Biotech, Inc.股票老虎,PharmaCyte Biotech, Inc.股票老虎国际,PharmaCyte Biotech, Inc.行情,PharmaCyte Biotech, Inc.股票行情,PharmaCyte Biotech, Inc.股价,PharmaCyte Biotech, Inc.股市,PharmaCyte Biotech, Inc.股票价格,PharmaCyte Biotech, Inc.股票交易,PharmaCyte Biotech, Inc.股票购买,PharmaCyte Biotech, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PharmaCyte Biotech, Inc.(PMCB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}